Clinical Trials

Overview

About this study

The purpose of the study is to develop and validate artificial Intelligence (AI) enabled sceening tools for the early detection of congenital heart disease (CHD) in newborns. This involves developing algorithms based electrocardiogram (ECG) and phonocardiogram data, both retrospective and prospectively. The study aims to improve upon current screening methods, such as pulse-oximetry, which have limitations in detecting both critical and non-critical CHD. By leveraging AI technology, the study seeks to enhance the accuracy and accessibility of CHD screening, potentially leading to better outcomes for affected newborns. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information